Registered outcomes28

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

21 to 28 of 28

List	Outcome	Time frame	Description
Secondary	Change From Baseline in Chest Circumference	At Month 12 and 24
Secondary	Ratio Between Chest and Head Circumferences	At Month 12 and 24
Secondary	Percentage of Participants With the Ability to Swallow and to Feed Orally	At Month 12, 24, 36, 48 and 60
Secondary	Change From Baseline in Compound Muscle Action Potential (CMAP) Amplitude	At Month 12 and 24	Measured by CMAP
Secondary	Measurement of Pharmacodynamic Marker Levels in Blood	Day 1, 56, 196, 364, 728 and at early withdrawal
Secondary	Percentage of Participants With Adverse Events	Up to 7 years	Adverse event severity is determined according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5 (NCI CTCAE) v5
Secondary	Ophthalmological Examination as Appropriate for Age	Up to 7 years
Secondary	Plasma Concentration of Risdiplam and Its Metabolites to Characterize the PK Profile	Up to 7 years

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03779334/registered?page=2